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Mycobacterium tuberculosis (M. tuberculosis) causes an enormous burden of disease worldwide. As a central aspect of its
pathogenesis, M. tuberculosis grows in macrophages, and host and microbe influence each other’s metabolism. To define
the metabolic impact of M. tuberculosis infection, we performed global metabolic profiling of M. tuberculosis–infected
macrophages. M. tuberculosis induced metabolic hallmarks of inflammatory macrophages and a prominent signature of
cholesterol metabolism. We found that infected macrophages accumulate cholestenone, a mycobacterial-derived, oxidized
derivative of cholesterol. We demonstrated that the accumulation of cholestenone in infected macrophages depended on
the M. tuberculosis enzyme 3β-hydroxysteroid dehydrogenase (3β-Hsd) and correlated with pathogen burden. Because
cholestenone is not a substantial human metabolite, we hypothesized it might be diagnostic of M. tuberculosis infection
in clinical samples. Indeed, in 2 geographically distinct cohorts, sputum cholestenone levels distinguished subjects with
tuberculosis (TB) from TB-negative controls who presented with TB-like symptoms. We also found country-specific detection
of cholestenone in plasma samples from M. tuberculosis–infected subjects. While cholestenone was previously thought to be
an intermediate required for cholesterol degradation by M. tuberculosis, we found that M. tuberculosis can utilize cholesterol
for growth without making cholestenone. Thus, the accumulation of cholestenone in clinical samples suggests it has an
alternative role in pathogenesis and could be a clinically useful biomarker of TB infection.

Introduction

Mycobacterium tuberculosis (M. tuberculosis), the causative agent of
tuberculosis (TB), is an intracellular pathogen that causes an enormous worldwide burden of disease. It is estimated that 1.7 billion
people are latently infected with M. tuberculosis, and in 2017 there
were an estimated 10 million new cases of TB and 1.4 million deaths
(1). The diagnosis of active TB is often challenging, leading to long
delays in treatment. Treatment generally requires multiple antibiotics for a minimum of 6 months, and relapse occurs in 3% to 5%
of treated patients (2). In some patients, long courses of therapy
expose patients unnecessarily to side effects of antibiotics, while
in other patients, stopping therapy prematurely leads to relapse. As
such, there is a large unmet medical need for new therapeutics; rapid, sensitive, and affordable diagnostic methods; and biomarkers to
allow tailored therapy and to guide clinical decision making.
As a central aspect of its pathogenesis, M. tuberculosis grows in
macrophages, and host and microbe influence each other’s metabolism. Previous work in our lab investigated immuno-metabolic
dynamics of the host during M. tuberculosis infection. We showed that
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M. tuberculosis induces miR-33 to control host pathways critical for its
intracellular survival, including lipid metabolism and autophagy (3).
We also showed that intracellular growth of M. tuberculosis depends
on macrophage fatty acid catabolism and that inhibiting host fatty
acid catabolism enhances immune effector functions against M.
tuberculosis (4). Given the increasing appreciation of the link between
metabolism and immunity, we performed unbiased metabolomics
to explore perturbations in metabolic pathways during M. tuberculosis infection. We found that M. tuberculosis–infected macrophages
preferentially utilize glucose, channel TCA cycle intermediates for
itaconate production, and induce perturbations in redox homeostasis. As previous reports have shown, such metabolic changes support
host antimicrobial functions by allowing rapid ATP and NADPH production, enhancing oxidative stress and inflammation, and providing raw materials for plasma membrane synthesis and protein export
(5–7). In addition to these immuno-metabolic changes, we found a
prominent metabolic signature of cholesterol metabolism, with
cholestenone (4-cholesten-3-one) the second most discriminating
metabolite between infected and uninfected cells.
Host cholesterol can serve as a carbon source that feeds
mycobacterial central metabolism and the biosynthesis of methyl-branched fatty acids (8, 9). M. tuberculosis induces the formation
of lipid-droplet–filled or foamy macrophages (10–13). In these foamy
macrophages, M. tuberculosis–containing phagosomes are in close
approximation to host lipid droplets (11). M. tuberculosis also grows
extracellularly in the lipid-rich caseum of necrotic granulomas (14).
Cholesterol utilization by M. tuberculosis has been linked to dormancy and persistence (8, 15). M. tuberculosis oxidizes host cholesterol
1
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Figure 1. Global metabolomic profiling identifies
metabolites that discriminate M. tuberculosis–infected from uninfected macrophages. (A) Murine BMDMs
were incubated with M. tuberculosis H37Rv at MOI
5 for 4 hours after which extracellular bacteria were
removed. Infected macrophages were harvested 3 hpi
and 24 hpi for metabolomics analyses. At each time
point, uninfected cells were used as controls. (B) A
biochemical importance plot indicating the top 30
metabolites that differentiate between uninfected
and M. tuberculosis–infected macrophages. The mean
decrease accuracy quantifies the importance of a
metabolite to the prediction accuracy of the model.
A higher value shows that the metabolite has more
importance to group separation. The color of each
molecule indicates the metabolic pathway with which
it is associated. This plot is derived from random
forest analysis of the metabolomics profile of 507
biochemicals obtained from 19 samples. See methods
for additional details.

to cholestenone, which is thought to be a necessary intermediate in
cholesterol degradation. M. tuberculosis is able to completely degrade
cholesterol through a process involving enzymes of the KstR1 regulon, which degrade the side chain and A/B ring, and the KstR2 regulon, which metabolize the C/D ring (16). Humans do not have a
similar pathway to degrade cholesterol. Instead, cholesterol serves
as a critical component of cellular membranes and is used for biosynthesis of bile acids, steroid hormones, and vitamin D. This raises
the possibility that M. tuberculosis–specific cholesterol metabolites
might be involved in pathogenesis and serve as unique biomarkers
of infection. This led us to investigate the mechanism of cholesterol oxidation and the potential utility of cholesterol metabolites as
TB biomarkers. Indeed, using clinical samples from 2 cohorts of
patients, recruited from Peru and Vietnam, we found that cholestenone is a candidate biomarker of TB infection.

Results

Global metabolomics reveals immuno-metabolic changes and a signature of cholesterol metabolism associated with M. tuberculosis infection.
To identify a metabolic signature of M. tuberculosis infection, we
globally profiled metabolites from M. tuberculosis–infected bone
marrow–derived macrophages (BMDMs) at 7 and 28 hours postinfection (hpi) compared with uninfected cells (Figure 1A). Over
500 metabolites were reported from pathways involved in carbohydrate, lipid, nucleotide, and amino acid metabolism, redox
homeostasis, inflammation, and xenobiotics (Supplemental Table
1; supplemental material available online with this article; https://
doi.org/10.1172/JCI152509DS1). Since metabolite extraction was
performed without separating intracellular M. tuberculosis from
2

the macrophages, the identified metabolites
could be from host or pathogen. Principle component analysis demonstrated clear separation
of infected and uninfected samples, indicative
of distinct metabolic phenotypes (Supplemental Figure 1). Using random forest analysis, we
identified 30 metabolites that distinguished M.
tuberculosis–infected from uninfected macrophages and ranked them according to their predictive power (Figure 1B). While differences in any individual metabolite from this
global screen would require further validation, the overall changes
were consistent with the idea that M. tuberculosis infection induces a Warburg-like glycolytic shift in macrophage metabolism (17),
enhances flux to the pentose phosphate pathway for NADPH production, elevates itaconate levels, and alters redox homeostasis
(gamma-glutamyl amino acids and pterin derivatives) (Figure 1B,
Figure 2, Supplemental Table 1, and Supplemental Figures 2–4, see
Supplemental Material for details). Compared with controls, M.
tuberculosis–infected macrophages showed elevated itaconate, the
fourth most discriminating metabolite (Figure 1B and Figure 2).
Classically activated macrophages have a characteristic TCA cycle
breakpoint, which allows conversion of cis-aconitate to the antimicrobial metabolite itaconate by the enzyme Irg1 (7, 18). Irg1 protects against severe pathology in M. tuberculosis–infected mice (19).
M. tuberculosis infection also enhanced levels of nucleotide sugars
(UDP-glucuronate), which may be used by the host for glycosylation
reactions or by M. tuberculosis to support cell wall biosynthesis (Supplemental Figure 2, Supplemental Text). Overall, infection-induced
molecules suggested upregulation of pathways that are metabolic
hallmarks of an inflammatory macrophage phenotype.
The other notable signature that we observed was related to
cholesterol utilization. The second most infection-discriminating
metabolite was cholestenone, an oxidized derivative of cholesterol
(Figure 2 and Figure 3A). Many of the other top metabolites, including methylsuccinate, methylcitrate, and 2-aminoadipate, were all
previously enriched when M. tuberculosis was grown in vitro with
cholesterol as compared with glycerol (ref. 20 and Figure 2). The top
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Figure 2. Metabolic signature of M. tuberculosis infection reflects changes in cholesterol metabolism. Schematic summarizing the relationship between
key metabolic pathways and biochemicals that changed in response to infection. Metabolites that are likely from macrophages are orange, and those from
M. tuberculosis are purple. Box plots show scaled intensity for relevant metabolites from the metabolomics screen in uninfected (Ctrl) and M. tuberculosis–
infected (TB) samples 3 hpi and 24 hpi. Box plots show median as a line and mean as ‘+’, and each dot represents data from a single replicate. Statistical
significance was calculated using ANOVA for all analytes identified in the screen. *P < 0.05, **P < 0.01, ###P ≤ 0.003, and ****P < 0.0001. Also see Supplemental Table 1 and Supplemental Text.

fifth discriminating metabolite was methylsuccinate, which may be
generated by cholesterol C and D ring degradation (Figure 1B, Figure 2, and refs. 20–22). It can also be produced through catabolism
of branched chain amino acids (23), but since we did not observe
major changes in valine and isoleucine catabolites, the most likely
source of methylsuccinate was degradation of host cholesterol by
intracellular M. tuberculosis (Supplemental Table 1). Degradation of
cholesterol and odd chain fatty acids by M. tuberculosis generates
propionyl-CoA, which is in equilibrium with propionylcarnitine,
another infection-induced metabolite identified in our screen (Figure 2). Propionyl-CoA feeds the methylmalonate pathway and methylcitrate cycle, which generate important products for synthesis of
bacterial virulence lipids and central carbon metabolism (Figure 2).
In response to infection, we detected significant increases of methylmalonate and 2-methylcitrate, 2 intermediates of these metabolic
pathways. Interestingly, itaconate inhibits host and M. tuberculosis
methylmalonyl-CoA mutase, which isomerizes methylmalonyl-CoA
to succinyl-CoA (24). Itaconate also inhibits M. tuberculosis isocitrate
lyase(s), which functions in the methylcitrate cycle (18, 25). Thus,
elevated itaconate may contribute to the observed elevation in methylmalonate and methylcitrate. Overall, our metabolomics screen
suggested dynamic immuno-metabolic changes attributable to

host-pathogen interactions. The results also pointed to the oxidation
and degradation of cholesterol by the bacilli. This is consistent with
a previous study in M. tuberculosis–infected THP-1 macrophages in
which the cholesterol metabolite 4,5-9,10-diseco-3-hydroxy-5,9,17tri-oxoandrosta-1(10),2-diene-4-oic acid (DSHA) was detected
(26). Our screening platform did not look for secosteroid and androstenedione-related metabolites that are intermediates in M. tuberculosis cholesterol degradation, such as DSHA, 4-androstenedione
(ADD), 9-hydroxy-androsta-1,4-diene-3,17-dione (9OHADD), and
3-hydroxy-9,10-seconandrost-1,3,5(10)-triene-9,17-dione (3-HSA)
(21). Despite this limitation, among a vast pool of host metabolites,
the apparent signature of cholesterol metabolism was noteworthy.
Since cholestenone is a unique metabolite that is likely to depend
upon host and M. tuberculosis cometabolism, we further investigated
its production during intracellular infection.
Cholestenone abundance correlates with bacterial burden and duration of M. tuberculosis infection. We infected BMDMs with M. tuberculosis at different multiplicities of infection (MOI) and estimated
cholestenone abundance at various time points over 5 days of infection using mass spectrometry. During metabolite extraction, we
spiked cell lysates with premeasured d5-cholestenone as an internal
standard to verify the identity of the metabolite and to quantify its
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Figure 3. Macrophage cholestenone levels correlate with M. tuberculosis burden and duration of infection. (A) Chemical structures of cholesterol and
cholestenone showing A–D rings (red text). The 3-hydroxyl group of cholesterol is dehydrogenated to a keto moiety in the A ring in cholestenone (highlighted in green). (B) Cholestenone was quantified from BMDMs infected with M. tuberculosis at MOI 1, 5, and 10, at 3, 24, 72, and 120 hpi. Uninfected (UI)
cells or those infected with heat-killed M. tuberculosis (HK) were used as controls. Plot shows average of 2 independent experiments.*P = 0.03, **P = 0.007
for 120 hours, calculated using Mann-Whitney test. (C) Cholestenone levels in PMA-differentiated THP-1 macrophages that were uninfected or M. tuberculosis–infected at MOI 10, 72 hpi. (D) Growth of M. tuberculosis was compared in minimal medium supplemented with either a vehicle control, 100 μg/mL
25-HC, or 100 μg/mL cholesterol. Plot shows values from 1 experiment representative of 3 independent experiments. (E) Cholestenone abundance and (F)
corresponding M. tuberculosis CFU in IFN-γ–activated and naive BMDMs that were uninfected or M. tuberculosis–infected at MOI 10 at the indicated time
points. (G and H) The direct effect of cholestenone on M. tuberculosis growth was assessed in culture medium using absorbance measurements (G) and
CFU (H). (C, E, and F) Plots show mean ± SEM from at least 3 independent experiments. **P = 0.007, ****P < 0.0001 calculated using Student’s t test (C),
and 1-way ANOVA with Tukey’s multiple comparisons test (E and F). (G and H) Plots show average of 2 independent experiments. Also see Supplemental
Figure 6. (C and E) The dotted line on the y axis represents the limit of detection accuracy as determined by the standard curve. For all macrophage experiments, one million cells were infected and the samples were extracted in 500 μL 80 % methanol solution containing 0.1 μg internal standard. The methods
used for calculating cholestenone concentrations are detailed in the Supplemental Material.

relative abundance (Supplemental Figure 5). We found that cholestenone levels increased with increasing bacterial burden and duration
of infection (Figure 3B and Supplemental Figure 6A). As a control,
we used heat-killed M. tuberculosis, which confirmed that cholestenone production requires live bacilli. We also verified that M. tuberculosis infection generated cholestenone in human cells by infecting
THP-1 macrophages, a human monocytic cell line (Figure 3C). In
addition, we examined the levels of methylmalonate, methylcitrate,
and methylsuccinate, additional top differential metabolites related
to cholesterol degradation, and itaconate. We included the corresponding internal standards for each metabolite during extraction
(Supplemental Figure 5). We confirmed that M. tuberculosis infection
enhanced the level of methylsuccinate and itaconate 72 hpi (Supplemental Figure 6B). We did not detect differences in the abundance
4

of methylcitrate and methylmalonate 72 hpi, so their apparent elevation at earlier time points in the primary screen requires further
validation. Thus, we confirmed a sustained increase in abundance
of methylsuccinate, cholestenone, and itaconate in response to M.
tuberculosis infection of BMDMs.
Recent reports show that IFN-γ induces the expression of cholesterol 25-hydroxylase, which converts cholesterol to the immunomodulatory oxysterol 25-hydroxycholesterol (25-HC) which
can have antimicrobial activity (27, 28). Since IFN-γ activation also
enhances the ability of macrophages to control M. tuberculosis, we
investigated the ability of M. tuberculosis to metabolize 25-HC. First,
we examined whether M. tuberculosis can use 25-HC as a carbon
source and found that M. tuberculosis grew in minimal media supplemented with 25-HC as the sole carbon source (Figure 3D). Next,
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we infected IFN-γ–activated and untreated BMDMs, and compared
cholestenone abundance at various time points of infection (Figure
3E). At the same time, we generated a standard curve to determine
the linear range of the assay and to establish the concentration of
cholestenone in samples (Supplemental Figure 7A). In addition, we
quantified total cholesterol, M. tuberculosis burden, and macrophage
cell viability at each time point (Figure 3F and Supplemental Figure
6). M. tuberculosis infected both naive and IFN-γ–activated macrophages equally. However, macrophages that had been pretreated
with IFN-γ had significantly reduced cholestenone abundance early
(4 hours) after infection. At 72 hpi and 120 hpi, cholestenone levels
trended lower but were not significantly different between treated
and untreated macrophages (Figure 3, E and F) even though bacterial CFUs were significantly lower in the IFN-γ–treated macrophages.
Thus, IFN-γ treatment appears to influence the relationship between
bacterial burden and cholestenone levels. Although total cholesterol levels were not affected by IFN-γ (Supplemental Figure 6), IFN-γ
profoundly affects the intracellular niche of the M. tuberculosis as
well as host metabolism, including altering the distribution of different host cholesterol pools (28). Thus, IFN-γ might alter cholestenone
production or subsequent metabolism by affecting host or bacterial
metabolism. To determine whether cholestenone could have direct
antimicrobial activity against M. tuberculosis, we evaluated its effect
on bacilli growing in broth culture. We found that cholestenone was
not directly toxic to M. tuberculosis, even at concentrations in vast
excess of what was found in macrophages (Figure 3, G and H). Taken
together, our findings demonstrate that M. tuberculosis infection of
IFN-γ–activated and naive macrophages leads to the production of
cholestenone, an oxidized derivative of host cholesterol.
3β-hydroxysteroid dehydrogenase, not ChoD, converts cholesterol to cholestenone. As far as we are aware, there is no mammalian
enzyme that is reported to convert cholesterol to cholestenone.
There is ambiguity in the literature as to the identity of the enzyme
that is responsible for cholestenone production by M. tuberculosis
and whether the oxidation step is required for cholesterol degradation. The enzymes that have been evaluated in previous studies are
3β-hydroxysteroid dehydrogenase (3β-Hsd, Rv1106c) and cholesterol oxidase (ChoD, Rv3409). Purified 3β-Hsd has cholesterol oxidase
activity in vitro (29, 30). However, in the H37Rv strain background,
a Δhsd mutant metabolizes cholesterol to degradative intermediates
and grows on cholesterol (31). ChoD (Rv3409) has been investigated as an alternative cholesterol oxidase, but the H37Rv Δhsd ΔchoD
double mutant is also reported to grow on cholesterol (31). Given the
apparent contradictory results, we sought to identify the cholesterol
oxidase(s) in our strain and determine whether it was required for
cholesterol degradation. We used oligonucleotide-mediated recombineering followed by Bxb1 integrase targeting (ORBIT) to delete
hsd (Δhsd) or choD (ΔchoD) in the H37Rv strain background (see
Supplemental Methods; ref. 32). We grew these strains in liquid cultures using either minimal or a nutrient-rich media (7H9 with oleic
acid, albumin, dextrose, catalase, and glycerol), supplemented with
either vehicle control or 0.1 mg/mL cholesterol solubilized in tyloxapol/ethanol (Figure 4, A and B). We monitored growth of WT and
mutant strains and quantified cholesterol and cholestenone abundance. As expected, the mutants and parental strain grew similarly
in nutrient-rich media, irrespective of whether it was supplemented
with cholesterol (Figure 4B). In these conditions, cholesterol levels

decreased over time and became undetectable by day 5. In minimal
media, all the strains grew when cholesterol was provided as the sole
carbon source (Figure 4A). The ΔchoD strain was indistinguishable
from WT, whereas the Δhsd mutant had a slight growth delay during
the exponential growth phase, accompanied by a slight delay in
depleting cholesterol in the media (Figure 4A). However, despite the
modest impact on cholesterol utilization, we found a drastic decrease
in cholestenone production by the Δhsd mutant compared with the
WT strain and ΔchoD mutant, which was restored by complementation (Figure 4C). Thus, neither ChoD nor 3β-Hsd is required for
growth of M. tuberculosis on cholesterol as the sole carbon source,
although 3β-Hsd was required for cholestenone production. The
modest growth delay of Δhsd was reproducible and restored by
complementation (Figure 4D). Together, these results indicate that
3β-Hsd is required for cholestenone production by M. tuberculosis
in vitro. Importantly, since the Δhsd mutant is capable of growing
on cholesterol even though it cannot produce cholestenone (Figure
4, A and C), our results show that cholestenone production is not
absolutely essential for cholesterol utilization in M. tuberculosis. To
determine whether 3β-Hsd was essential for cholestenone production during intracellular infection, we compared cholestenone abundance in BMDMs infected with M. tuberculosis and the Δhsd mutant.
Cholestenone was not detected in macrophages infected with the
Δhsd mutant, and genetic complementation restored the production
of cholestenone (Figure 4E). In BMDMs that were pretreated with
IFN-γ, cholestenone made during M. tuberculosis infection was also
dependent on the bacterial 3β-Hsd (Supplemental Figure 6E). The
same was found in PMA-differentiated THP-1 macrophages (Figure
4F). The dependence of cholestenone on bacterial 3β-Hsd was not
due to attenuation of the mutant strain, as intracellular uptake and
growth of Δhsd was similar to WT M. tuberculosis (Supplemental Figure 6, F and G). Last, to determine whether nontuberculous mycobacterium (NTM) also generated cholestenone during infection, we
infected BMDMs with Mycobacterium abscessus, an important cause
of pulmonary disease, particularly in patients with cystic fibrosis. As
for M. tuberculosis, we found that in macrophages infected with M.
abscessus, host cholesterol was oxidized to cholestenone (Figure 4G).
To conclude, we confirmed that 3β-Hsd is required for the oxidation
of cholesterol into cholestenone by M. tuberculosis; however, 3β-Hsd
is not required for cholesterol utilization by M. tuberculosis. In addition, cholestenone is also produced during macrophage infection
with M. abscessus, consistent with the presence of cholesterol oxidases in mycobacterial species beyond M. tuberculosis (33).
Cholestenone levels are elevated in clinical samples from patients
with TB. Based on our in vitro results, we investigated whether
methylsuccinate, cholestenone, and itaconate are more abundant
in patients with TB compared with controls. We obtained paired
sputum and plasma samples from 80 patients from Peru and Vietnam. All patients were at least 18 years old and HIV negative. The
TB-positive group (n = 20 per country) were positive by sputum
smear microscopy and culture. Importantly, subjects in the control group (n = 20 per country) had symptoms compatible with TB
infection, but they were negative for active TB by sputum smear
microscopy, culture, and Xpert, as well as having negative Quanti-FERON assay results. There were no significant differences in the
age range or sex of TB-positive or -negative subjects in either country
(Table 1). Their clinical symptoms, such as chest pain, recent weight
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Figure 4. M. tuberculosis 3β-hydroxysteroid dehydrogenase, not ChoD, catalyzes oxidation of cholesterol to cholestenone. (A and B) Growth of H37Rv,
Δhsd, Δhsd att:pCH89 (ΔhsdpCH89), and ΔchoD in (A) minimal media and (B) 7H9 supplemented with OADC. Cultures supplemented with cholesterol are
indicated by closed symbols, while open symbols represent cultures with the vehicle control. Cholesterol abundance in the cultures is represented with the
dotted lines. (C) Cholestenone abundance measured during growth of H37Rv, Δhsd, ΔhsdpCH89, and ΔchoD in 7H9 supplemented with OADC and cholesterol (100 μg/mL). (D) Growth of H37Rv, Δhsd, ΔhsdpCH89, and ΔchoD in minimal media supplemented with cholesterol, expressed as the ratio of OD600nm for
each strain normalized to H37Rv. Plot shows the mean and SEM from 3 independent experiments, *P < 0.05 indicates significance between H37Rv and Δhsd
and was done using Student’s t test. (E and F) Cholestenone abundance at 72 hpi in (E) BMDMs and (F) PMA-differentiated THP-1 macrophages infected
with WT M. tuberculosis, Δhsd, H37Rv att:pCH89 (H37RvpCH89), or ΔhsdpCH89. (G) Cholestenone abundance in BMDMs infected with M. abscessus at MOI
1, 24 hpi. (A–C) Graphs are representative of 3 independent experiments. (E and G) Data shows (E) mean ± SD from at least 2 independent experiments, and
(F and G) SEM from 3 independent experiments. (E–G) *P = 0.01, **P ≤ 0.004, ****P < 0.0001 calculated using (E and F) 1-way ANOVA with Tukey’s multiple
comparisons test and (G) Student’s t test. UI, uninfected. (C, E, and F) The dotted line on the y axis represents the limit of detection accuracy as determined
by the standard curve. For all macrophage experiments, one million cells were infected and the samples were extracted in 500 μL 80 % methanol solution
containing 0.1 μg internal standard. The methods used for calculating cholestenone concentrations are detailed in the Supplemental Material.

loss, fever, dyspnea, and hemoptysis were recorded (Table 1 and
Supplemental Tables 2 and 3). Differences between the Peruvian
and Vietnamese populations are shown in Supplemental Table 2. We
extracted metabolites from sputum and plasma samples and measured methylsuccinate, cholestenone, and itaconate levels by mass
spectrometry. Since itaconate is produced as a general host response
to infection, we thought it might be present in both TB-infected and
uninfected subjects, since the TB-negative subjects might have other
infections. However, in most subjects, itaconate was undetectable,
and we found no significant differences in levels of itaconate or
methylsuccinate in sputum or plasma of TB-positive subjects compared with controls (Supplemental Figure 8). We anticipated that
cholestenone would be TB-specific, since we could not find any evidence that it was made by common pulmonary pathogens. Indeed,
the sputum of TB-positive subjects had significantly higher cholestenone abundance compared with controls, in both the Peru and
Vietnam cohorts (Figure 5A, Mann-Whitney P < 0.01 and P < 0.0001
respectively). To assess the precision of the mass spectrometry quantification, we repeated the sputum processing and mass spectrometry analysis for 80 samples and found a high degree of correlation
between the independent experiments (Supplemental Figure 7B).
Receiver operating characteristic (ROC) analysis showed that the
levels of cholestenone in sputum had high TB diagnostic potential
6

in Vietnam (AUC = 0.96), and Peru (AUC = 0.75; Figure 5B). In addition to higher levels of cholestenone in sputum, patients with TB in
the Peru cohort also had significantly higher plasma cholestenone
compared with controls (Figure 5C, t test P < 0.001). Remarkably,
plasma levels of cholestenone were predictive of TB infection in subjects from Peru (Figure 5D; AUC = 0.80). However, plasma cholestenone levels were not significantly associated with TB infection status
in the Vietnam cohort and showed poor predictive value (Figure 5,
C and D; AUC = 0.64). While sputum cholestenone levels were elevated in subjects with TB, sputum cholesterol levels were not different between TB-infected and control subjects and were therefore of
little predictive value (Figure 5, E and F). Plasma cholesterol levels
in both cohorts were significant lower in subjects with TB compared
with controls (Figure 5G, t test P < 0.01 and P < 0.001 for Peru and
Vietnam cohorts, respectively). Consistent with these observations,
ROC plots for cholesterol abundance in plasma show a similar
performance for both cohorts (Figure 5H, AUC = 0.81 in Vietnam
and AUC = 0.78 in Peru). Absolute quantification values and statistical parameters for cholestenone and cholesterol concentrations in
these samples are reported in Supplemental Table 4. Furthermore,
a ratio of sputum cholestenone and plasma cholesterol was significantly increased in TB-positive subjects compared with controls
in both countries, and using the ratio improved the discriminating
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Table 1. Summary statistics for clinical variables by country and infection status
Variable
Sex
Female
Male
Age, years; mean (SD)
History of BCG vaccination
History of active TB
Normal chest x-ray
Chest pain
Dyspnea
Fever
Hemoptysis
Malaise
Night sweats
Cough
Recent weight loss (without diet)

Peru
TB negative (n = 20)

TB positive (n = 20)

9/20 (45%)
11/20 (55%)
33 (11.6)
18/19 (90%)
0/8 (0%)
14/17 (82%)
18/20 (90%)
11/20 (55%)
6/20 (30%)
3/20 (15%)
20/20 (100%)
4/20 (20%)
20/20 (100%)
7/20 (35%)

6/20 (30%)
14/20 (70%)
30 (10.9)
20/20 (100%)
1/20 (5%)
1/19 (5%)
13/20 (65%)
14/20 (70%)
11/20 (55%)
8/20 (40%)
19/20 (95%)
12/20 (60%)
20/20 (100%)
15/20 (75%)

P valueA

Vietnam
TB negative (n = 20)

TB positive (n = 20)

7/20 (35%)
13/20 (65%)
51 (15.6)
9/17 (45%)
5/20 (25%)
0/20 (0%)
9/20 (45%)
14/20 (70%)
12/20 (60%)
4/20 (20%)
16/20 (80%)
6/20 (30%)
20/20 (100%)
6/20 (30%)

5/20 (25%)
15/20 (75%)
47 (14.1)
13/15 (65%)
3/20 (15%)
0/20 (0%)
11/20 (55%)
8/20 (40%)
13/20 (65%)
5/15 (25%)
14/20 (70%)
9/20 (45%)
20/20 (100%)
11/20 (55%)

0.327
0.471
0.487
>0.999
<.001
0.058
0.327
0.110
0.155
>0.999
0.022
>0.999
0.011

P valueA
0.49
0.412
0.06
0.695
>0.999
0.527
0.057
0.744
>0.999
0.716
0.327
>0.999
0.11

Results reported as n (%) or mean (range). AP values obtained using a χ2, Fisher’s exact, or t test, as appropriate.

potential of these metabolites (Figure 6, A and B; AUC = 0.995 in
Vietnam cohort, AUC = 0.78 in Peru cohort). Consistent with the
observations for cholestenone plasma levels in TB-positive subjects
from Peru, the ratio of plasma cholestenone and plasma cholesterol was significantly higher in TB-positive subjects from Peru than in
controls and had a high diagnostic accuracy (Figure 6, C and D, AUC
= 0.90 in Peru). To conclude, we found that bacterial-derived cholestenone, which is a dominant metabolic signature of M. tuberculosis
infection in macrophages, is elevated in samples from TB-infected
subjects in a clinical setting.
Cholestenone abundance in sputum of patients with TB correlates
with infection burden. Next, we assessed whether clinical characteristics of the TB-positive subjects influenced cholestenone and
cholesterol levels in sputum or plasma (Supplemental Table 3).
First, we grouped TB-positive patients from both Peru and Vietnam
(n = 40) according to sputum grade (2+ or 3+), and compared each
group with TB-negative subjects (n = 40; Figure 7). We found that
the cholestenone levels in sputum were higher for the 2+ subjects
compared with TB-negative subjects (Figure 7A, adjusted P < 0.01),
and a further increase was seen in sputum of the 3+ subjects compared with 2+ subjects (Figure 7A, adjusted P < 0.001), suggesting
that sputum cholestenone abundance correlates with M. tuberculosis
burden in the lungs. In contrast, there was no difference in plasma
cholestenone levels based on sputum grade (Figure 7B). Cholesterol
levels in sputum were also not different between subjects based on
sputum grade (Figure 7C). Plasma cholesterol levels were decreased
in 2+ TB-positive and 3+ TB-positive subjects compared with
TB-negative subjects, however there was no difference between 2+
and 3+ subjects (Figure 7D). Next, we grouped the TB-positive subjects from both countries (n = 40) and investigated whether metabolite levels were associated with other clinical parameters such the
subject’s sex or presence of specific clinical symptoms (Supplemental Table 3). We found no clinical parameter that was significantly
associated with cholestenone or cholesterol levels in the sputum of
TB-positive subjects (Supplemental Table 3). Plasma cholesterol,

however, was significantly lower in patients with hemoptysis, a sign
of advanced disease (Supplemental Table 3; t test P < 0.05). To conclude, we show that sputum cholestenone level in patients with TB
correlates with the degree of smear positivity, suggesting it reflects
pulmonary pathogen burden.

Discussion

In the present study, we interrogated the metabolic landscape
of M. tuberculosis–infected macrophages. We found that the host
recalibrates its metabolism to support immune effector functions.
M. tuberculosis infection induces a Warburg-like glycolytic shift,
enhances flux to the pentose phosphate pathway, and modifies the
TCA cycle for generating the antimycobacterial metabolite itaconate, the top fourth differential biochemical in our screen. This intracellular milieu poses a challenge for most microbes, but M. tuberculosis is highly adapted to survive this environment. We found that
the most prominent metabolic signature of M. tuberculosis infection
is likely to reflect bacterial cholesterol degradation. Bacterial cholesterol metabolism results in propionyl-CoA, which is metabolized through the methyl citrate and methylmalonyl pathway, and
propionyl-CoA, 2-methylcitrate, and methylmalonate are infection-induced metabolites. In addition, previous work has shown
that growing M. tuberculosis in the presence of cholesterol results in
elevated levels of methylsuccinate and 2-aminoadipate (20), also
top differential metabolites in our study. We cannot infer anything
about the abundance of other metabolites of cholesterol degradation
by M. tuberculosis, such as ADD, 9OHADD, DSHA, or 3-HSA (21),
because they were not included in the panel of queried metabolites
in the screening platform. Since humans do not degrade cholesterol
through a similar pathway, this raised the possibility that unique cholesterol metabolites, such as cholestenone, might be biomarkers for
infection. Indeed, we found that the oxidized cholesterol metabolite
cholestenone accumulates in M. tuberculosis–infected macrophages,
and cholestenone levels in sputum correlate with active TB disease
in 2 geographically distinct cohorts. While cholesterol utilization
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Figure 5. Cholestenone levels are elevated in clinical samples from TB patients. Levels of metabolites from clinical samples from TB-negative (n = 20 per
country) and TB-positive subjects (n = 20 per country). (A) Sputum cholestenone level and (B) corresponding ROC curve. (C) Plasma cholestenone level and (D)
corresponding ROC curve. (E) Cholesterol level in sputum and (F) corresponding ROC curves. (G) Cholesterol level in plasma and (H) corresponding ROC curves.
Statistical analyses were done using the Mann-Whitney test for sputum samples and Student’s t tests for plasma samples. **P < 0.01, ***P < 0.001, ****P <
0.0001. The methods used for calculating cholestenone concentrations are detailed in the Supplemental Material. Metabolite abundance is reported in unprocessed samples (plasma or nonliquefied sputum).

by M. tuberculosis has been linked to dormancy and persistence (8,
15), our data suggest that M. tuberculosis metabolizes cholesterol
during active infection in people, consistent with expression profiling showing activation of the KstR regulon in M. tuberculosis isolated
from sputum (34). Our data in macrophages suggest that intracellular M. tuberculosis has access to host cholesterol, and we anticipate
that extracellular bacilli would also be able to metabolize cholesterol
present extracellularly in caseum or sputum.
8

Our data suggest that the vast majority of cholestenone present
during M. tuberculosis infection is derived by host-pathogen cometabolism, with the host providing cholesterol and the M. tuberculosis
3β-Hsd enzyme converting it to cholestenone. What is the evidence
in support of this idea? First, recombinant M. tuberculosis 3β-Hsd has
been shown to convert cholesterol to cholestenone in vitro (29, 35).
M. tuberculosis lacking Rv1106c, the gene encoding 3β-Hsd, fail to
convert cholesterol to cholestenone when growing in liquid culture,
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Figure 6. Ratio of cholestenone to plasma cholesterol in clinical samples from TB patients improves the diagnostic accuracy. Ratios of metabolites from
clinical samples from TB-negative (n = 20 per country) and TB-positive subjects (n = 20 per country). (A) Ratio of sputum cholestenone and plasma cholesterol
of control and TB-positive subjects from both countries and the (B) corresponding ROC curve. (C) Ratio of plasma cholestenone and plasma cholesterol in control patients and patients with TB from both countries, and the (D) corresponding ROC curve. (A and C) The ratios were determined on a per-subject basis and
were multiplied by a factor 106 for clarity. Statistical analyses were done using the Mann-Whitney test for sputum samples and Student’s t tests for plasma
samples. **P < 0.01, ***P < 0.001, ****P < 0.0001. The methods used for calculating cholestenone concentrations are detailed in the Supplemental Material.

as shown by others (29) and verified by us (Figure 4C). We found
that in macrophages the abundance of cholestenone that accumulates upon M. tuberculosis infection depends upon duration and MOI
(Figure 3B). Importantly, cholestenone production in macrophages
also depends on the bacteria being alive and having the hsd gene
(Figure 3B, Figure 4, E and F, and Supplemental Figure 6E). Thus,
while it is theoretically possible that the cholestenone produced in
macrophages is made by a host enzyme in response to WT but not
Δhsd mutant bacilli, the most straightforward explanation is that
the cholestenone made during infection comes from 3β-Hsd of the
bacilli. In addition, although humans have several 3β-HSD enzymes
that bear 29% to 35% identity to the one in M. tuberculosis, as far as
we are aware, no mammalian enzyme is reported to convert cholesterol to cholestenone. When we examined available published
data sets, we found that the mammalian 3β-hydroxysteroid dehydrogenases (HSD3B1 and HSD3B2) do not appear to be expressed
in M. tuberculosis–infected murine macrophages, M. tuberculosis–
infected human macrophages, and IFN-γ activated murine macrophages (36–38). This is not surprising since they are expressed in
steroidogenic tissue where they dehydrogenate steroid hormones.
Therefore, all the data combined suggest that M. tuberculosis 3β-Hsd
converts cholesterol to cholestenone during macrophage infection.
Although the evidence strongly suggest that M. tuberculosis is
the source of cholestenone during macrophage infections, how is it
then that we detected low levels of cholestenone in plasma of subjects without TB? These subjects had plasma cholestenone levels
in the range of 5 to 32 ng/mL (Supplemental Table 4), consistent
with a previous report that demonstrated levels of 30.4 ± 8.5 ng/
mL from a pooled sample of plasma from 100 individuals representative of the US population (39). HSD3B1 and HSD3B2 catalyze the

conversion of 3β-hydroxy steroids, which lack the side chain found
on cholesterol, to the 3-keto configuration. They are expressed in the
adrenals, ovaries, and testes, where they carry out an essential step
in production of progesterone, androstenedione, and testosterone.
HSD3B7 converts the 3β-hydroxy of 7α-hydroxycholesterol to the
3-keto configuration during bile acid synthesis. Cholestenone is not
reported as an intermediate in either of these pathways. Thus, the
source of the baseline cholestenone in the subjects without TB is not
clear, but 2 recent publications suggest that it may be derived from
cholesterol dehydrogenases expressed from uncultured members of
the microbiome (40, 41). Thus, while our findings support the idea
that in TB-infected subjects the elevated cholestenone is largely M.
tuberculosis–derived, it could theoretically be microbiome-derived or
the result of a yet-to-be-defined host enzyme.
We found that although 3β-Hsd is required for cholestenone
production, it is not required for cholesterol utilization, at least in the
H37Rv strain background. This was somewhat surprising because
cholesterol oxidation to cholestenone is often considered an initial
event in cholesterol degradation. Cholesterol is degraded through
β-oxidation of the cholesterol side chain and cleavage of the A and
B rings, followed by degradation of the C and D rings (21). Side
chain degradation is initiated by oxidation of the side chain at C26.
In H37Rv, CYP125 and CYP142 can both perform this initiating step,
and since both cholesterol and cholestenone are known substrates
of CYP125 and CYP142 (42), it is not surprising that this could occur
without 3β-Hsd. However, the first enzyme involved in AB ring
cleavage, KstD (Rv3537), strongly prefers androstendione (AD) as a
substrate, which has a ketone at the third carbon, compared with a
substrate with a 3-hydroxy (43). It is possible that in the absence of
3β-Hsd, a different enzyme acts during or after cholesterol side chain
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Figure 7. Cholestenone abundance in sputum of patients with TB correlates with infection burden. Levels of metabolites are plotted for TB-negative
subjects and TB-positive subjects grouped according to sputum grade, for (A) cholestenone in sputum, (B) cholestenone in plasma, (C) cholesterol in sputum, (D) cholesterol in plasma, (E) the ratio of cholestenone in sputum divided by cholesterol in plasma, (F) the ratio of cholestenone in plasma divided by
cholesterol in plasma. Results are shown for each country (n = 40) as well as both countries pooled (n = 80). The ratios were determined on a per-subject
basis and are shown multiplied by a factor 106 for clarity. Statistical analyses were done using the Kruskal-Wallis test (blue asterisks) followed by pairwise
comparisons with the Mann-Whitney test with the Benjamini-Hochberg correction for multiple comparisons. The resulting adjusted P values are shown
with black asterisks. For all statistical tests, significance is indicated with the following: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Lack of asterisks indicates P > 0.05. The methods used for calculating cholestenone concentrations are detailed in the Supplemental Material. Metabolite abundance is
reported in unprocessed samples (plasma or nonliquefied sputum).

degradation, for example, by converting the 3-hydroxy of dehydroepiandrosterone to the 3-ketone of AD. Brzostek et al showed that the
Δhsd ΔchoD double mutant in the H37Rv strain background makes
AD and 9-hydroxy androstendione (9OHAD), consistent with the
idea that there is an enzyme other than 3β-Hsd and ChoD that can
generate the ketone. It is also possible that there is metabolic flexibility and a ketone at C3 is not absolutely essential for M. tuberculosis to grow on cholesterol. To understand differences in how cholesterol and cholestenone are degraded in the absence of 3β-Hsd will
require dedicated studies with labeled cholesterol and cholestenone.
It should be pointed out that our study is in agreement with 2 previous reports on the role of 3β-Hsd in cholesterol degradation and
may resolve why they were seemingly at odds with one another (29,
31). As reported by Yang et al. (29), we validated that M. tuberculosis
3β-Hsd is the major cholesterol-oxidizing enzyme that generates cholestenone, whereas ChoD appears to be dispensable for this activity
(Figure 4C). As reported by Brzostek et al. (31), 3β-Hsd is not required
for utilization of cholesterol. Thus, the apparent discrepancy between
10

these previous studies is explained by the finding that the ability of M.
tuberculosis to grow on cholesterol does not depend on the oxidation
of cholesterol to cholestenone.
Previous studies have shown that cholestenone disrupts lipid rafts, membrane fluidity, and cell signaling in mammalian cells
(44–48), and recent work shows that cholestenone has antimicrobial
activity against Helicobacter pylori (49). We found that during macrophage infections cholestenone appears to accumulate over time.
Whether cholestenone remains associated with the bacilli or traffics
to host membranes is an area for future investigation. Given that it
is detected in both sputum and plasma in clinical samples, it seems
likely that it is widely distributed and could have a biological impact.
Since 3β-Hsd can also oxidize oxysterols, such as pregnenolone (29),
M. tuberculosis might also modify steroid hormones. Interestingly,
Mycobacterium leprae has lost the genes for cholesterol catabolism,
but retains hsd and the ability to make cholestenone (50, 51). In
addition, in M. tuberculosis Rv1106c/hsd is not transcriptionally regulated with other genes required for cholesterol metabolism (52).
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Combined, these observations suggest that cholestenone or other
3β-Hsd–generated host-pathogen cometabolites might be involved
in pathogenesis. As described for tryptophan cometabolism (53), our
work suggests that utilization of host cholesterol by M. tuberculosis
has a role beyond bacterial nutrition.
Cholestenone does not appear to be a metabolite made by most
pulmonary pathogens either. The literature suggests that cholestenone can be produced by a limited number of microbes that infect
humans including Mycobacteria, Rhodococcus, and Nocardia (54).
In addition, we performed a literature review on the top bacterial
causes of pulmonary infections and only identified reports of cholesterol oxidase activity by ChoD orthologs in Acinetobacter (55),
Pseudomonas (56–58), and Serratia (59). However, there are several
studies showing that putative cholesterol oxidases of Pseudomonas
produce hydroperoxycholestenone (HCEO) rather than cholestenone (56–58). In addition, outside of Mycobacteria, there are very
little data available on 3β-Hsd proteins in prokaryotes. Two recent
publications report 3β-Hsd orthologs in bacterial species of the
human gut microbiota (40, 41). To our knowledge, no other reports
describe 3β-Hsd family proteins in bacterial species outside of
Mycobacteria. Thus, we hypothesized that cholestenone might be a
specific differential diagnosis biomarker of active TB disease, generated by the cometabolism of host and pathogen. Indeed, we found
that cholestenone levels in sputum correlated with TB infection status in human patients. In our study, the control group consisted of
subjects presenting with symptoms consistent with TB, but in whom
M. tuberculosis infection was ruled out. This suggests that the significantly elevated level of cholestenone in the TB-positive group is
specific to M. tuberculosis infection rather than a more general marker of lung infection or inflammation. We also observed hypocholesterolemia in TB patient plasma in both Peru and Vietnam, a finding
previously documented in populations in Turkey and Ethiopia (60,
61). While there are many reasons this might be, it is tempting to
speculate that consumption of cholesterol by M. tuberculosis contributes to reduced levels in the host. Taken together, a ratio of sputum cholestenone and plasma cholesterol showed excellent predictive accuracy for diagnosing TB in both Peru and Vietnam cohorts.
Interestingly, we found that plasma cholestenone levels also
correlated with TB infection status, but only in the Peruvian population. In sputum, the TB diagnostic potential of cholestenone
was higher in subjects from Vietnam (AUC = 0.96) than in those
from Peru (AUC = 0.75). What might account for these differences? Cholestenone might be metabolized differently in the 2 populations because of differences in bacterial strains or host genetics.
Since different lineages of M. tuberculosis predominate in Peru and
Vietnam (62), there might be differences in how the bacilli metabolize cholesterol, which could contribute to differences in metabolites detected in people. Hsd is uniformly present in M. tuberculosis
isolates, but it might be regulated differently or other cholesterol
metabolic genes may vary by lineage. Since different lineages have
also been shown to have different predilection for extra-pulmonary disease manifestations, the plasma levels may reflect these
differences. Our knowledge of how cholestenone is metabolized in
humans is extremely limited. For example, if the Vietnamese cohort
hydroxylates cholestenone or otherwise modifies it in plasma, we
would not detect the modified species. In addition, differences in
metabolism by gut microbiota might impact metabolite levels in the

different human populations (40, 41). Studies in rats and patients
with cerebrotendinous xanthomatosis show that cholestenone can
be converted into cholestanol in the liver (63, 64). In addition, alveolar macrophages express CYP27A1, a sterol 27-hydroxylase that
converts cholesterol to cholestenoic acid (65). CYP27A1 hydroxylates cholestenone at a much higher rate than it modifies cholesterol
(66). Thus, conversion of cholestenone to 27-hydroxycholestenone
or oxidation of 25-hydroxylated metabolites of cholesterol that are
induced by interferon signaling might vary between the Peruvian
and Vietnamese populations. Thus, future investigation to understand the basis of the differences between the 2 populations will
be important and might identify cholestenone-related metabolites
that would be superior TB biomarkers in both sputum and plasma.
While the performance of cholestenone in sputum would fall short
of the WHO target product profile for a TB disease biomarker in
Peru, evaluating additional cholestenone-related species may lead
to a superior test. A non-sputum-based diagnostic is a high priority
for TB diagnostics (67). In Peru, we found that the ratio of cholestenone to cholesterol in plasma samples performed extremely well
as a diagnostic for active TB (AUC = 0.90). It will be critical to see if
this can be improved upon and adapted to other populations.
We also found that cholestenone levels in sputum correlated with the degree of smear positivity. If sputum cholestenone
reflects disease burden, then sputum levels might be used to monitor treatment. One limitation of our study is that smear positivity
is an imperfect measure of disease burden, and all of our subjects
had a high level of smear positivity. It will be important to follow
cholestenone levels in patients with TB longitudinally to determine
whether it declines with therapy, or can predict cure or relapse. It
will also be important to evaluate cholestenone levels in patients
with latent TB, extrapulmonary TB, smear-negative disease, and
with comorbidities such as HIV infection and diabetes. Although
a mass spectrometry–based assay of M. tuberculosis disease burden
would be useful in research settings, to be a useful clinical tool in
resource-constrained, high-burden countries will require translating it into a point-of-care test.
Homologs of 3β-Hsd have been annotated in the genomes of
most NTM species (33), and we found that M. abscessus also produces cholestenone during infection. Thus, cholestenone might be
a useful biomarker for NTM infections as well. While TB incidence
has declined in the United States, infections with NTM are rising
(68). NTM infections require extremely long courses of treatment,
usually more than a year, and they are often more challenging to
treat than M. tuberculosis because of limited antibiotic options.
Biomarkers that could guide clinical decision making would be
extremely useful. While isolation of M. tuberculosis from a sputum
sample is always diagnostic of TB infection, isolation of NTM can
occur because of environmental contamination. Detection of cholestenone could be a rapid way to distinguish true infection from
contamination. In addition, a mass spectrometry–based test is feasible in clinical microbiology laboratories in high income settings
where NTM infections are an increasing problem.
We show that cholestenone is a prominent metabolic signature of
mycobacterial infections, and M. tuberculosis uses the cholesterol oxidase 3β-Hsd to produce it. While there are a number of M. tuberculosis–derived molecules that have been pursued for diagnostic and biomarker purposes (2), as far as we are aware, cholestenone is unique in
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being the result of active bacterial-host cometabolism. Recent efforts
to develop novel diagnostics and biomarkers have focused on detecting a distinctive signature of the host response to TB infection (69).
One challenge for host-based diagnostics is that with clinical use,
coinfections and comorbidities impact the host signatures. Thus, to
date there has been considerable progress identifying TB biomarkers,
but efforts continue to be hampered by paucibacillary disease and
heterogeneity of the host response. Our findings indicate that cholestenone and related cometabolites should be further evaluated for
their role in pathogenesis and as potential TB biomarkers.

Methods

Bacterial strains. M. tuberculosis (H37Rv strain) was grown aerobically
at 37°C in Middlebrook 7H9 broth with 0.05% Tyloxapol, 0.2 % glycerol, and OADC (oleic acid-albumin-dextrose-catalase; catalog 212351;
BD Biosciences). When required, antibiotics were added in the culture
media with the following concentrations: 25 μg/mL kanamycin, 50 μg/
mL hygromycin, and 25 μg/mL zeocin. The strains used in this study,
details for their construction, and primers used can be found in the
Supplemental Methods and Supplemental Tables 5 and 6. The mutant
strains are isogenic derivatives of H37Rv, built using ORBIT (Oligonucleotide-mediated Recombineering followed by Bxb1 Integrase Targeting) mediated mutagenesis (32) and confirmed by PCR analysis. The
Δhsd mutant was complemented with an integrating plasmid (pCH89),
containing the full Hsd operon (Rv1106c- Rv1109c). PDIM production
by the strains was confirmed by mass spectrometry. Details of plasmid
construction can be found in Supplemental Methods. The pKM464 and
pKM461 plasmids were gifts from Kenan Murphy and Chris Sassetti
(University of Massachusetts Medical School).
Cell culture. Bone marrow–derived macrophages (BMDMs) were
obtained from 8- to 12-week-old C57Bl/6 mice that were obtained from
The Jackson Laboratory. Bone marrow was flushed from the femurs and
tibia of mice as described (4). BMDMs and THP-1 cells (American Type
Tissue Collection) were maintained as previously described (4). To promote macrophage differentiation, THP-1 cells were treated with 100 nM
phorbol myristate acetate (PMA; Sigma) for 24 hours before infection.
BMDMs were activated with IFN-γ (Thermo Fisher Scientific, catalog
PMC4031) at a concentration of 100 U/mL.
Global metabolomics profiling. For global metabolic profiling,
BMDMs isolated from 8 C57Bl/6 mice (aged 8–12 weeks obtained
from The Jackson Laboratory) were pooled and used for 4 experimental groups: uninfected and M. tuberculosis–infected, at 3 and 24 hour
time points. Each group had 5 replicates (n = 20 samples total). Fifteen
million murine BMDMs were infected with H37Rv at an MOI of 5 for
4 hours. Cells were then washed to remove extracellular bacteria and
maintained in culture medium for 3 or 24 hours. At the respective time
points, BMDMs were washed twice with sterile Hank’s Balanced Salt
Solution (HBSS, Gibco), and metabolites were extracted in 80% methanol (Sigma) in water (Corning) containing premeasured internal standards provided by Metabolon. The samples were stored at –80°C prior
to shipping to Metabolon for further processing and analyses. At Metabolon, the samples were prepared using the automated MicroLab STAR
system from Hamilton Company. After addition of recovery standards
and protein removal, the extracts were divided into fractions for analysis as follows: 2 separate reverse phase (RP)/ultra-performance liquid
chromatography mass spectometry (UPLC-MS)/MS with positive ion
mode electrospray ionization (ESI), RP/UPLC-MS/MS with negative
12

ion mode ESI, and hydrophilic interaction liquid chromatography (HILIC)/UPLC-MS/MS with negative ion mode ESI. All methods utilized a
Waters Acquity UPLC and a Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray
ionization (HESI-II) source and Orbitrap mass analyzer operated at
35,000 mass resolution. Raw data were extracted, peak-identified, and
QC processed using Metabolon’s hardware and software that are built
on a web-service platform using Microsoft’s NET technologies. Metabolon maintains a library based on authenticated standards that contain
the retention time/index (RI), mass-to-charge ratio, and chromatographic data (including MS/MS spectral data) on all molecules present
in the library. To distinguish biochemicals, their identifications were
based on 3 criteria: retention index within a narrow RI window of the
proposed identification, accurate mass match to the library ± 10 ppm,
and the MS/MS forward and reverse scores between the experimental
data and authentic standards. Peaks were quantified using AUC. Missing values were imputed with the minimum observed value for each
compound. To determine scaled intensity, the raw area counts for each
biochemical were rescaled to set the median equal to 1. Statistical analyses were conducted on the scaled and imputed data. Refer to Supplemental Methods for additional details.
Random forest analysis. Random forest represents a supervised classification technique based on biochemical profile of the data set. Random forest analysis was done in RStudio using the package ‘randomForest’ with sampsize = rep(m1, l1) and ntree = 50,000, where m1 is half
the smallest group in the random forest, l1 is the number of groups, and
ntree is the number of trees. To build the random forest, all 507 metabolites were included from 19 of 20 samples (one replicate was considered an outlier; see Supplemental Figure 1). The analysis misidentified 1
infected sample resulting in an out-of-bag (OOB) error of 1/19 and predictive accuracy of 95%.
In vitro growth assays. To assess M. tuberculosis growth in defined carbon sources, the strains were grown in minimal media (0.5 g/L asparagine, 1 g/L KH2PO4, 2.5 g/L Na2HPO4, 5 mg/L ferric ammonium citrate,
0.5 g/L MgSO4-7H2O, 0.5 mg/L CaCl2, and 0.1 mg/L ZnSO4), adapted
from ref. 8. As needed, carbon sources were provided either through
0.1 % glycerol (vol/vol) or 0.01 % cholesterol (wt/vol). Cholesterol was
added using a 100× stock solution prepared in tyloxapol/ethanol (1:1).
Growth was monitored using a cell density meter and normalized to the
optical density of the culture medium. Throughout the growth curves,
bacterial samples were withdrawn for cholesterol and cholestenone
quantification. For cholesterol quantification, at defined time points, culture samples were frozen at –80°C, until they were processed together for
total cholesterol (free cholesterol + esterified cholesterol) quantification
using the Amplex Red Cholesterol Assay Kit (Invitrogen). For cholestenone analysis, the bacterial culture samples were centrifugated, washed
twice in PBS, and the pellets stored at –80°C until they were processed
for mass spectrometry. For the investigation of cholestenone bactericidal
activity on M. tuberculosis, cholestenone was prepared in ethanol as 100×
stock solutions to achieve indicated final concentrations.
Chemicals and reagents. The following compounds were used
as internal standards or reference compounds: (±)-2-methyl-d3succinic-2,3,3-d3 acid (catalog M329046; Toronto Research Chemicals [TRC]), methylmalonic acid-d3 (catalog M318862; TRC), 2-methylcitric acid-d3 (catalog M265082; TRC), itaconic acid-13C5 (catalog
I931004; TRC), 4-cholesten-3-one-2,2,4,6,6-d5 (catalog D-5467;
CDN Isotopes) 4-cholesten-3-one (catalog 188174; Sigma-Aldrich),
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itaconic acid (catalog I29204; Sigma-Aldrich), methylcitric acid (catalog M265080; TRC), methylmalonic acid (catalog M318862; TRC),
and methylsuccinic acid (catalog M329045: TRC). All HPLC grade solvents were purchased from Sigma.
Mass spectrometry identification of metabolites. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods were used to
analyze metabolites extracted from samples derived from either bacterial pellets, infected cells, or human clinical samples obtained from
the Foundation for Innovative New Diagnostics (FIND). Samples were
extracted with 80% methanol, and the appropriate internal standards
were included in the extraction buffer at final concentrations: 0.20 μg/
mL 4-cholesten-3-one-2,2,4,6,6-d5, 0.1 μg/mL (±)-2-methyl-succinic-2,3,3-d3 acid, 1 μg/mL itaconic acid-13C5, 0.1 μg/mL methylmalonic
acid-d3, or 0.1 μg/mL 2-methylcitric acid-d3.
All samples were extracted with 80% methanol for 10 minutes
at room temperature, followed by centrifugation for 10 minutes at
21,130g, and the supernatants were sent to the Washington University
Metabolomics Facility for LC-MS/MS analysis. Bacterial pellets from in
vitro growth were resuspended in 500 μL 80% methanol. For samples
obtained from infected macrophages, 1 × 106 cells were infected, and at
defined time points they were washed twice in PBS and extracted with
500 μL 80% methanol. Sputum samples were liquefied before methanol extraction by adding Sputolysin (Calbiochem) in a 1:1 proportion.
Plasma and sputum samples were added to 100% methanol to achieve
a volume of 500 μL extraction buffer at a final concentration of 80%
methanol. The measurement of 4-cholesten-3-one, methylsuccinic
acid, itaconic acid was performed with a Shimadzu 20AD HPLC system
(Shimadzu) coupled to a Q Exactive mass spectrometer or 4000QTRAP
mass spectrometer (AB Sciex). The 4-cholesten-3-one was separated on
an ACE C8 (4.6 × 100 mm, 3 μm) column (Mac-Mod Analytical) and
detected with positive multiple reaction monitoring (MRM) mode. The
methylsuccinic acid and itaconic acid were separated on a ZIC-HILIC
(4.6 × 150 mm, 3 μm) column and detected with negative MRM mode.
Quality control samples were prepared by pooling a portion of the study
samples, and were injected after every 10 study samples to monitor
instrument performance. Data processing was conducted with Analyst
1.6.3. The methods to calculate cholestenone concentration are detailed
in Supplemental Methods. Metabolite abundance is reported for unprocessed samples (plasma or nonliquefied sputum).
Bacterial infections. For in vitro macrophage assays, a log-phase
culture of M. tuberculosis was pelleted and resuspended in macrophage
culture medium. Bacterial single-cell suspensions were prepared by
low speed centrifugation (60g for 8 minutes). The number of M. tuberculosis in the resulting supernatant was estimated by measuring absorbance at 600 nm, followed by infection of macrophages at a MOI of
1, 5, or 10. The infectious dose administered was calculated by plating
CFUs from an aliquot of the bacterial suspension. After 4 hours, macrophages were washed 3 times with warm media to remove extracellular
bacteria. To estimate intracellular M. tuberculosis growth, infected macrophages were lysed in 0.06% sodium dodecylsulfate (SDS) solution at
the indicated time points, and serial dilutions of the lysates were plated on 7H10 agar plates (catalog 283810; BD Biosciences) containing
glycerol and Middlebrook OADC enrichment (oleic acid-albumin-dextrose-catalase, catalog 212351; BD Biosciences). The number of CFUs
was calculated 14 to 21 days later.
Clinical study design. The goal of the study was to determine whether cholestenone, cholesterol, methylsuccinate, or itaconate levels were

different in TB-positive subjects compared with TB-negative controls. We
obtained paired sputum and plasma samples from 20 TB-positive and 20
TB-negative subjects from Peru and Vietnam from FIND (https://www.
finddx.org/specimen-bank/specimens-tb/). The TB-negative samples
were from subjects who tested negative on sputum smear, culture, Xpert,
and Quantiferon testing. These subjects had symptoms consistent with
TB, but their symptoms improved or resolved at follow-up without treatment. The TB-positive samples were from sputum smear, culture, and
Xpert-positive subjects who had symptoms consistent with M. tuberculosis
infection. All patients were adults (≥ 18 years) and confirmed HIV negative. The study was exploratory, and no power analysis was performed.
We requested 160 samples from 80 subjects from 2 different geographic
areas. The investigators who processed the samples and quantified the
metabolites were blinded to sample identity. No outliers were excluded.
Total cholesterol was estimated in the plasma and liquefied sputum samples using the Amplex Red Cholesterol Assay kit.
Statistics. Violin plots and ROC plots were generated with RStudio version 1.3.1073 (70) using packages described in the Supplemental
Methods. For the global metabolomic study, analysis of variance (ANOVA) was performed for all analytes identified in the screen. Differences
between other experimental groups were assessed using 2-tailed Student’s t test, Mann-Whitney U test, or 1-way ANOVA models followed by
Tukey’s post hoc tests, as indicated in figure legends. Analyses evaluating differences between TB groups and clinical characteristics included
independent groups t tests, Mann-Whitney U tests, χ2 tests, or Fisher’s
exact tests, as appropriate. A P value less than 0.05 was considered significant. All analyses were conducted using GraphPad Prism software
(www.graphpad.com), SAS version 9.4 (SAS Institute Inc.), or RStudio
version 1.3.1073. Figure 1, Figure 2 and graphical abstract were created
with BioRender using original templates.
Study approval. The Washington University School of Medicine
Institutional Animal Care and Use Committee approved all the work
with mice. Euthanasia was performed in accordance with the 2020
AVMA Guidelines for the Euthanasia of Animals. Human clinical samples
were obtained from FIND (https://www.finddx.org/specimen-bank/
specimens-tb/). All specimens were collected at qualified clinics under a
protocol approved by an Institutional Review Board and with informed
consent from patients. FIND follows good clinical and laboratory practice in obtaining and processing samples.
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